Presence of immunoreactive endothelin in human milk  by Lam, Hing-Chung et al.
Volume 261, number 1, 184-186 FEBS 08097 February 1990 
Presence of immunoreactive ndothelin in human milk 
Hing-Chung Lam, Kazuhiro Takahashi, Mohammed A. Ghatei and Stephen R. Bloom 
Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, Du Cane Road, London, WI2 ONN. England 
Received 18 December 1989 
Endothelin-like immunoreactivity was detected in human milk at a concentration of 6.8 & 1.6 pmol/l (mean + SEM; n = 16) using a highly sensitive 
radioimmunoassay. Gel filtration and fast protein liquid chromatography (FPLC) verified the identity of the endothelin. FPLC revealed 4 peaks, 
one eluting just after the void volume, and the other three in the positions of endothelin-1, -2, and -3, respectively. 
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1. INTRODUCTION 
Endothelin-1 (ET-l), a 21 amino acid peptide, is a po- 
tent and long-lasting vasoconstrictor. It was originally 
isolated, and its structure determined, from the condi- 
tioned medium of cultured porcine endothelial cells [ 11. 
Subsequently, a family of ET-like peptides, namely 
ET-I, ET-2 and ET-3, which have similar but not iden- 
tical structures, were found to be encoded by three 
distinct genes, each present in the human, rat and por- 
cine genome [2]. ET-like immunoreactivity has been 
detected in human plasma [3] and urine [4]. Many pep- 
tides and growth factors are present in mammalian milk 
[5], and physiological roles have been suggested for 
them in the lactating mother and the suckling neonate 
[6-91. Using our recently developed, sensitive and 
specific radioimmunoassay [lo] together with gel 
chromatography and fast protein liquid chromato- 
graphy (FPLC), we have investigated the concentration 
and molecular forms of immunoreactive endothelin 
(IR-ET) in human milk. 
2. MATERIALS AND METHODS 
2.1. Milk extraction 
Fresh human milk samples were obtained from 16 lactating 
mothers after the colostrum phase was completed and stored at 
- 20°C immediately. All subjects were less than eight days postpar- 
tum. After thawing, milk samples were centrifuged at 4°C for 20 min 
to separate the fat and aqueous layers. The aqueous milk (5 ml) was 
acidified with 2 ml 4% acetic acid and extracted immediately using 
Sep-Pak Cl8 cartridges (Waters Associates, MA, USA) as previously 
described [lo]. For chromatographic characterization of milk IR-ET, 
a lOO-ml aliquot of pooled human milk was extracted as above, and 
applied to gel permeation and FPLC, respectively. The recovery of 
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synthetic ET added to human milk was 62.4*4.4% (n = 5) following 
the extraction procedure. 
2.2. Gel permeation chromatography 
Reconstituted Sep-Paked human milk extracts were centrifuged to 
remove particulate material and loaded onto a Sephadex G-25 Super- 
fine column (0.9 x 60 cm, Pharmacia, Uppsala, Sweden). The column 
was eluted at a flow rate of 3.5 ml/h at 4°C in 60 mM phosphate buf- 
fer (pH 7.4) containing 10 mM EDTA, 7 mM sodium azide, 0.2 M 
NaCl and 0.3% (w/v) bovine serum albumin. The positions of void 
volume and total volume were determined by dextran blue and Na?, 
respectively. 0.7-ml fractions were collected for RIA. The recovery of 
IR-ET in human milk extracted from the column was 80%. 
2.3. Fast protein liquid chromatography (FPLC) 
Human milk extracts were reconstituted in 0.1% (v/v) aqueous 
trifluoroacetic acid (TFA) and centrifuged prior to analysis by FPLC 
with a high-resolution reverse-phase (Pep RPC HR 5/5) C-18 column 
(Pharmacia, Uppsala, Sweden). The column was eluted with a gra- 
dient of acetonitrile from 15% to 35% (v/v) in water with 0.1% TFA 
over 1 h at a flow rate of 1 ml/min per fraction. Samples of each frac- 
tion were dried in a Savant vacuum centrifuge, reconstituted in assay 
buffer, and assayed. The recovery of IR-ET in human milk extract 
from the column was 95%. 
2.4. Stability of ET-l, ET-2, and ET-3 in human milk 
To examine the stability of ET in human milk, ET-l, 2, and 3 were 
incubated (1 pmol/ml milk) in human milk at room temperature for 
5 h. Then the milk samples were extracted by Sep-Pak Cl8 cartridges 
and loaded onto the FPLC. The IR-ET in each fraction was measured 
by RIA. 
2.5. Radioimmunoassay of IR-ET 
Radioimmunoassay of ET has been described previously in detail 
[lo], but the antibody used in the present study was obtained from a 
subsequent bleed of the immunogenic rabbit and gave increased sen- 
sitivity. This assay could detect changes of 0.1 fmol/tube at 95% con- 
fidence with duplicate tubes. The antibody showed 60% cross- 
reactivity with ET-2 and 70% with ET-3 (Peptide Institute, Osaka, 
Japan) but no cross-reaction with a-human atrial natriuretic peptide, 
neuropeptide Y, substance P, vasoactive intestinal peptide, peptide 
histidine methionine, glucagon, angiotensin II and ACTH. 
3. RESULTS AND DISCUSSION 
The dilution curves of human milk extract and the 
void volume peak from FPLC of human milk extract 
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paralleled the standard curve (fig. 1). The mean concen- positions of ET-l, ET-2 and ET-3, respectively. The 
tration of IR-ET in the milk from lactating mothers was nature of the void volume peak is unknown. However, 
6.8 t 1.6 pmol/l (range, 0.5-21.2 pmol/l, n = 16). This we have found a similar peak of FPLC from human 
is higher than the concentration found in normal plasma [ 1 l] and from human urine extracts (unpublish- 
human plasma (0.54 + 0.05 pmol/l, n = 19) [l 11. The ed observations). Incubation of exogenous ET-l, ET-2 
presence of IR-ET in human milk raises not only the and ET-3 in human milk for 5 h did not produce any 
question of its role there but also of its origin. The material eluting in the void volume peak position, so it 
higher concentration of IR-ET in milk as compared to is unlikely to be an extraction artifact or a degraded 
plasma implies either an active concentrating mecha- form of ET. As the 2-fold serial dilution of void volume 
nism in the mammary gland or an extravascular origin peak material paralleled the standard curve (fig.l), we 
for this peptide. suggest hat this peak represents a precursor of ET. 
Gel permeation chromatography of pooled human 
milk extract showed two immunoreactive components 
(fig.2). The first minor component which eluted just 
after the void volume could be a large molecular weight 
form of IR-ET and may be a precursor of ET. The se- 
cond major component comprised most of the eluted 
immunoreactivity in a broad peak sparing the elution 
positions of ET-l, ET-2 and ET-3. Sephadex G-25 gives 
different elution positions for ET-l, ET-2 and ET-3 in 
spite of their similar molecular weights, presumably due 
to their ring structure. 
FPLC of milk extracts resulted in 4 peaks (fig.3A), 
one just after the void volume and the other three in the 
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Fig.1. A standard curve for ET (M) and 2-fold serial dilution 
curves of normal human milk extract (+---+) and the second frac- 
tion of human milk extract from FPLC (w). Serial dilutions of 
the original milk volume are denoted above the curves. 
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Fig.2. Sephadex G-25 column chromatography of IR-ET in a pooled 
normal human milk extract. ET-l, ET-2, and ET-3, the elution posi- 
tions of standard ET-l, 2 and 3, respectively. 
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Fig.3. FPLC of IR-ET in: (A) a pooled normal human milk extract; 
(B) ET-l incubated in human milk at room temperature for 5 h; (C) 
ET-2 incubated in human milk for 5 h; (D) ET-3 incubated in human 
milk for 5 h. The dotted lines show a linear gradient of acetonitrile 
from 15% to 35%. 
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The total content of IR-ET in human milk with ex- 
ogenous ET-l decreased to 70% of its original value 
after 5 h incubation at room temperature (data not 
shown). FPLC showed that ET-l was converted to a 
form which eluted in a single peak at the position of 
ET-3 (fig.3B). This suggests that ET-l had become ox- 
idized. In contrast, the concentration of exogenous 
ET-2 and ET-3 did not decrease after 5 h incubation in 
milk (data not shown) and the elution profiles of FPLC 
showed a single peak in the positions of ET-2 (fig.3C) 
and ET-3, respectively (fig.3D). From these results, we 
cannot be certain that ET-3 exists in human milk, as a 
peak corresponding to ET-3 is produced by ET-l over 
a period of time. In addition, as the antiserum to ET-l 
used in this study showed 70% cross-reactivity with 
ET-3 and 60% with ET-2, greater amounts of IR-ET 
may be present in milk than we have been able to 
measure. 
ET has been reported to cause contraction in the rat 
gut [12] and we have recently shown that ET receptors 
are present in the gastrointestinal tract of rats [13]. It is 
therefore possible that ET in milk may have a 
physiological role in the development and motility of 
the gastrointestinal tract of the suckling neonate. 
In conclusion, the present study demonstrates for the 
first time the presence of IR-ET in human milk. Further 
studies are needed to investigate its possible functions in 
the lactating mother and the neonate. 
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